Last reviewed · How we verify
Rivaroxaban 10 mg
At a glance
| Generic name | Rivaroxaban 10 mg |
|---|---|
| Also known as | Xarelto, Jiangsu Zhongbang pharmaceutical CO., LTD; Serial numbers: H20203733, No intervention, Placebo, Xarelto 10mg |
| Sponsor | Hospital Alemão Oswaldo Cruz |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (PHASE3)
- Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis (PHASE1)
- Rivaroxaban in Idiopathic Membranous Nephropathy (PHASE4)
- Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis (PHASE4)
- Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies (NA)
- RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing (PHASE3)
- Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rivaroxaban 10 mg CI brief — competitive landscape report
- Rivaroxaban 10 mg updates RSS · CI watch RSS
- Hospital Alemão Oswaldo Cruz portfolio CI